References
- Corey-Bloom J, Anand R, Veach J, et al. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to slightly severe Alzheimer’s disease. Int J Geriatr Psychopharmacol. 1998;1:55–65.
- Cutler NR, Polinsky RJ, Sramek JJ, et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurol Scand. 1998;97:244–250.
- Lefevre G, Sedek G, Jhee SS, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther. 2008;83:106–114.
- Lefevre G, Sedek G, Huang HL, et al. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol. 2007;47:471–478.
- Lee DH, Choi YH, Cho KH, et al. A case of rivastigmine toxicity caused by transdermal patch. Am J Emerg Med. 2011;29:695.e1–695.e2.
- Lovborg H, Jonsson AK, Hagg S. A fatal outcome after unintentional overdosing of rivastigmine patches. Curr Drug Saf. 2012;7:30–32.
- Hoffman RS, Manini AF, Russell-Haders AL, et al. Use of pralidoxime without atropine in rivastigmine (carbamate) toxicity. Hum Exp Toxicol. 2009;28:599–602.
- Singh S, Bhardwaj U, Verma SK, et al. Hyperamylasemia and acute pancreatitis following anticholinesterase poisoning. Hum Exp Toxicol. 2007;26:467–471.
- Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998;20:634–647.
- Pinakini KS, Kumar TS. Serial cholinesterase estimation in carbamate poisoning. J Clin Forensic Med. 2006;13:274–276.
- Abdullat IM, Battah AH, Hadidi KA. The use of serial measurement of plasma cholinesterase in the management of acute poisoning with organophosphates and carbamates. Forensic Sci Int. 2006;162:126–130.
- Spencer CM, Noble S. Rivastigmine. A review of its use in Alzheimer's disease. Drugs Aging. 1998;13:391–411.